Archer Materials (ASX:AXE) integrated its graphene field effect transistor sensors with electrical readout circuitry in a new chip as it seeks to integrate the Biochip into an at-home testing device for
chronic kidney disease, according to a Thursday ASX filing.
The chips were fabricated at foundry partner VTT Technical Research Centre of Finland via a multi-project wafer run on a 200mm wafer. Chips from the wafer are being packaged for testing at the firm.
It will continue the integration work in parallel with the ongoing development of the Biochip. The Biochip development and integration activities will be targeted at having early prototypes of the system and demonstration of initial potassium testing accuracy performance early in 2026.
The Biochip needs to be integrated with cartridge fluidics for the delivery of the blood sample for sensing. Integrating the Biochip with miniaturized electronics is a key step in this regard.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。